112
Views
7
CrossRef citations to date
0
Altmetric
Research Article

A 90-day subchronic toxicity study of beta-calcium pyrophosphate in rat

, , &
Pages 277-282 | Received 01 Jan 2009, Accepted 10 Mar 2009, Published online: 19 Jun 2009

References

  • Dias, A.G., Lopes, M.A., Gibson, I.R., Santos, J.D. (2003). In vitro degradation studies of calcium phosphate glass ceramics prepared by controlled crystallization. J Non-Cryst Solids 330:81–89.
  • Ducheyne, P. (1987). Bioceramics: material characteristics versus in vivo behavior. J Biomed Mater Res 21:219–236.
  • Kitsugi, T., Yamamuro, T., Nakamura, T., Kotani, S., Kokubo, T., Takeuchi, H. (1993). Four calcium phosphate ceramics as bone substitutes for non-weight-bearing. Biomaterials 14:216–224.
  • Kitsugi, T., Yamamuro, T., Nakamura, T., Oka, M. (1995). Transmission electron microscopy observations at the interface of bone and four types of calcium phosphate ceramics with different calcium/phosphorus molar ratios. Biomaterials 16:1101–1107.
  • Lee, J.H., Lee, D.H., Ryu, H.S., Chang, B.S., Hong, K.S., Lee, C.K. (2003). Porous beta-calcium pyrophosphate as a bone graft substitute in a canine bone defect model. Key Eng Mater 240–242:399–402.
  • Lee, J.H., Ryu, H.S., Lee, D.S., Hong, K.S., Chang, B.S., Lee, C.K. (2005). Biomechanical and histomorphometric study on the bone-screw interface of bioactive ceramic-coated titanium screws. Biomaterials 26:3249–3257.
  • Rosenthal, A.K. (2000). Formation of calcium pyrophosphate crystal: biologic implications. Curr Opin Rheumatol 12:219–222.
  • Silcox, D.C., McCarty, D.J. (1974). Elevated inorganic pyrophosphate concentration in synovial fluid in osteoarthritis and pseudogout. J Lab Clin Med 83:518–531.
  • Tancred, D.C., McCormack, B.A., Carr, A.J. (1998). A quantitative study of the sintering and mechanical properties of hydroxyapatite/phosphate glass composites. Biomaterials 19:1735–1743.
  • U.S. FDA. (2006). Part 182—substances generally recognized as safe. Section 182.8223-calcium pyrophosphate. In: Code of Federal Regulations (CFR) Title 21—Food and Drugs (U.S. Food and Drugs Administration) (p 478 ). Washington, DC: U.S. Government Printing Office (GPO).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.